277 related articles for article (PubMed ID: 34502435)
1. Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Lee HW; Seo HK
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502435
[TBL] [Abstract][Full Text] [Related]
2. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
4. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
5. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
6. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
7. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
[TBL] [Abstract][Full Text] [Related]
8. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
9. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
10. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.
Benjamin DJ; Mar N; Rezazadeh Kalebasty A
Clin Med Insights Oncol; 2022; 16():11795549221126252. PubMed ID: 36186672
[TBL] [Abstract][Full Text] [Related]
13. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
14. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
16. The evolving treatment landscape of advanced urothelial carcinoma.
Andreev-Drakhlin AY; Egoryan G; Shah AY; Msaouel P; Alhalabi O; Gao J
Curr Opin Oncol; 2021 May; 33(3):221-230. PubMed ID: 33818541
[TBL] [Abstract][Full Text] [Related]
17. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
18. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
20. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]